An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants?

Anticoagulant therapy in elderly patients with atrial fibrillation and concomitant diseases is often the challenge for clinicians. The high risk of stroke is inherent in atrial fibrillation, and it increases when combined with coronary heart disease and chronic kidney disease. On the other hand, the comorbidity increases the risk of bleeding. Older age is also the risk factor of thrombotic and hemorrhagic complications. As a consequence, the choice of specific anticoagulant should be based on a solid evidences, obtained both from randomized clinical trials and from daily clinical practice. In the ROCKET AF trail the direct oral anticoagulant rivaroxaban showed a tendency to reduce the risk of thromboembolism by 20% compared with warfarin in the patients aged 75 years and older. The safety of rivaroxaban has been evaluated in the XANTUS POOLED program. According to the follow-up results for 12 months, more than 96% of patients didn't have any adverse event, and the number of patients with major bleeding was 1.5%. Several meta-analyzes reported a reduction of cardiovascular complications in patients treated by rivaroxaban. In the ROCKET AF trail, a “renal” dose of rivaroxaban (15 mg OD) was studied in patients with chronic kidney disease. The efficacy and safety of rivaroxaban were validated in this patients, and a simple algorithm for selecting the dose of this drug in patients with chronic kidney disease was provided.

1. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2020;ehaa612. DOI:10.1093/eurheartj/ehaa612.

2. Svennberg E., Engdahl J., Al-Khalili F., et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015;131(25):2176-84. DOI:10.1161/CIRCULATIONAHA.114.014343.

3. Gudmundsdottir K., Fredriksson T., Svennberg E., et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace. 2020;22(1):24-32. DOI:10.1093/europace/euz255.

4. Boriani G., Laroche C., Diemberger I., et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128:509-518. DOI:10.1016/j.amjmed.2014.11.026.

5. Siontis K.C., Gersh B.J., Killian J.M., et al. Typical, atypical, and asymptomatic presentations of newon-set atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm. 2016;13:1418-24. DOI:10.1016/j.hrthm.2016.03.003.

6. Golitsyn S.P., Panchenko E.P., Kropacheva E.S., et al. Diagnosis and treatment of atrial fibrillation. Eurasian Cardiology Journal. 2019;(4):4-85 (In Russ.) [Голицын С.П., Панченко Е.П., Кропачева Е.С., с соавт. Диагностика и лечение фибрилляции предсердий. Евразийский Кардиологический Журнал. 2019;(4):4-85].

7. Grond M., Jauss M., Hamann G., et al. Improved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic Stroke. 2013;44(12):3357-64. DOI:10.1161/STROKEAHA.113.001884

8. Wachter R., Groschel K., Gelbrich G., et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED): an open-label randomised controlled trial. Lancet Neurol. 2017;16(4):282-90. DOI:10.1016/S1474-4422(17)30002-9.

9. Jawad-Ul-Qamar M., Chua W., Purmah Y., et al. Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables. Open Heart. 2020;7:e001151. DOI:10.1136/openhrt-2019-001151.

10. Patel MR., Mahaffey KW., Garg J., et al, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. DOI:10.1056/NEJMoa1009638.

11. Halperin J.L., Hankey G.J., Wojdyla D.M., et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138-46. DOI:10.1161/CIRCULATIONAHA.113.005008.

12. Kirchhof P., Radaideh G., Kim YH., et al. Global Prospective Safety Analysis of Rivaroxaban. JACC. 2018;72(2):141-53. DOI:10.1016/j.jacc.2018.04.058.

13. Hanon О., Vidal J.S., Pisica-Donose G., et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2020 Dec 1;heartjnl-2020-317923. DOI:10.1136/heartjnl-2020-317923.

14. Coleman C.I., Weeda E.R., Nguyen E., et al. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018;4(4):328-9. DOI:10.1093/ehjqcco/qcx044.

15. Martinez B.K., Sood N., Bunz T., et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7(8):e008643. DOI:10.1161/JAHA.118.008643.

16. Yao X., Shah N., Sangaralingham L., et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-90. DOI:10.1016/j.jacc.2017.03.600.

17. Friberg L., Rosenqvist M., Lip G., Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298-307. DOI:10.1161/CIRCULATIONAHA.111.055079.

18. Gomez-Outes A., Lagunar-Rwz J., Terleira-Fernandez AI., et al. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. Am Coll Cardiol. 2016;68(23):2508-21. DOI:10.1016/j.jacc.2016.09.944.

19. Pastori D., Farcomeni A., Poli D., et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med. 2016;11(2):199-204. DOI:10.1007/s11739-015-1326-1.

20. Mak K.H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):pii:e001592. DOI:10.1136/bmjopen-2012-001592.

21. Chatterjee S., Sharma A., Uchino K., et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013;24(8):628-35. DOI:10.1097/MCA.0000000000000031.

22. Loke Y.K., Pradhan S., Ka-Yan Yeong J., et al. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707-17. DOI:10.1111/bcp.12376.

23. Weijs B., Blaauw Y., Rennenberg R.J., et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011;32:2555-62. DOI:10.1093/eurheartj/ehr226.

24. Andrews J., Psaltis PJ., Bayturan O., et al. Warfarin use is associated with progressive coronary arterial calcification: insights from serial intravascular ultrasound. JACC Cardiovasc Imaging. 2018;11:1315-23. DOI:10.1016/j.jcmg.2017.04.010.

25. Lee J., Nakanishi R., Li D., et al. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis. Am Heart J. 2018;206:127-30. DOI:10.1016/j.ahj.2018.08.007.

26. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011;4:26-32. DOI:10.1161/CIRCEP.110.957100.

27. Alonso A., Lopez F.L., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circula-tion.2011;123(25):2946-53. DOI:10.1161/CIRCULATIONAHA.111.020982.

28. Bansal N., Fan D., Hsu C., et al. Incident Atrial Fibrillation and Risk of Death in Adults With Chronic Kidney Disease. Journal of the American Heart Association. 2014;3(5):e001303. DOI:10.1161/JAHA.114.001303.

29. Wizemann V., Tong L., Satayathum S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney International. 2010;77(12):1098-106. DOI:10.1038/ki.2009.477.

30. Fordyce C.B., Hellkamp A.S., Lokhnygina Y., et al. On-Treatment Outcomes in Patients WithWorsening Renal Function With Rivaroxaban Compared With Warfarin Clinical Perspective: Insights From ROCKET AF. Circulation. 2016;134(1):37-47. DOI:10.1161/CIR.0000000000000763.

31. Brodsky S.V., Collins M., Park E., et al. Warfarin therapy that results in an international normalization ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010;115:c142-6. DOI:10.1159/000312877.

32. Brodsky S.V., Nadasdy T., Rovin B.H., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80:181-9. DOI:10.1038/ki.2011.44.

33. Chatrou M.L., Winckers K., Hackeng T.M., et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012;26(4):155-66. DOI:10.1016/j.blre.2012.03.002.

34. Yao X., Tangri N., Gersh B., et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;70(21):2621-32. DOI:10.1016/j.jacc.2017.09.1087.

35. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Heart Rhythm. 2019;16(8):e66-e93. DOI:10.1016/j.hrthm.2019.01.024.

36. Diener H-C., Hart RG., Koudstaal PJ., et al. Atrial Fibrillation and Cognitive Function. J Am Coll Cardiol. 2019;73(5):612-9. DOI:10.1016/j.jacc.2018.10.077.

37. Da Silva R.M.F.L., Miranda C.M., Liu T., et al. Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, andEffect of Anticoagulation. Frontiers in Neuroscience. 2019;13:18. DOI:10.3389/fnins.2019.00018.

38. Rivard L., Khairy P. Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation. Can J Cardiol. 2017;33(12):1556-64. DOI:10.1016/j.cjca.2017.09.024.

39. Salas M., Veld B.A., Linden P.D. Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study. Clinical Pharmacology & Therapeutics. 2001;70(6):561-6. DOI:10.1067/mcp.2001.119812.

40. El-Saifi N., Moyle W., Jones C., Tuffaha H., et al. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. Journal of Pharmacy Practice. 2018;31(3):322-34. DOI:10.1177/0897190017710524.